Tolterodine: all 48 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled TrialNot yet recruitingNCT07114640Phase 3
• Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled StudyRecruitingNCT05946902Phase 4
• TReating Incontinence for Underlying Mental and Physical HealthRecruitingNCT05362292Phase 4
• A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)CompletedNCT02138747Phase 4Results posted
• Treatment of Symptoms After Stent Placement for Urinary Tract ObstructionCompletedNCT01741454Phase 4Results posted
• Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1CompletedNCT01661621Phase 4Results posted
• The Effect of Terazosin and Tolterodine on Ureteral Stent Related SymptomsCompletedNCT01530243Phase 2/3Results posted
• A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)TerminatedNCT01500382Phase 1Results posted
• A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)CompletedNCT01314872Phase 2Results posted
• Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive BladderTerminatedNCT01302938Phase 4Results posted
• Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)CompletedNCT00939120Phase 4Results posted
• A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)CompletedNCT00768521Phase 1Results posted
• Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder SymptomsCompletedNCT00465894Not applicableResults posted
• Overactive Bladder Innovative Therapy Trial (OrBIT)CompletedNCT00448175Phase 4Results posted
• A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.TerminatedNCT00323635Phase 4Results posted
• Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea SyndromeCompletedNCT05250245Phase 4
• Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.CompletedNCT04500860Phase 1
• Efficacy Comparison Between Different Management Strategies for Consistent OAB in Patients With SVMs After SurgeryStatus unknownNCT03280316Not applicable
• the Indications and Clinical Efficacy of Pelvic Organ Prolapse SurgeryStatus unknownNCT02599311Phase 3
• Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of TolterodineCompletedNCT01964183Phase 4
• Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder SyndromeCompletedNCT01824420Phase 4
• Pharmacokinetics and Relative Bioavailability StudyCompletedNCT01521767Phase 1
• Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder SyndromeCompletedNCT01503580Not applicable
• Bladder Wall Blood Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarincs for Female Overactive Bladder Syndrome.CompletedNCT01282840Not applicable
• STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic StudyCompletedNCT01181505Phase 1
• A Study of YM178 in Subjects With Symptoms of Overactive BladderCompletedNCT01043666Phase 3
• Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy SubjectsCompletedNCT01036035Phase 1
• Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy VolunteersCompletedNCT01011036Phase 3
• Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)CompletedNCT00922506Phase 4
• Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic ProstatitisStatus unknownNCT00913315Not applicable
• Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive BladderCompletedNCT00836381Phase 4
• Solifenacin Succinate Versus Tolterodine 4mg Once DailyCompletedNCT00802373Phase 3
• Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive BladderCompletedNCT00746681Phase 2
• Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) PatientsCompletedNCT00730535Phase 4
• Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor OveractivityCompletedNCT00648310Phase 2/3
• A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.CompletedNCT00645281Phase 4
• The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive BladderCompletedNCT00553657Phase 1
• Pharmacological vs Surgical Treatment for Mixed IncontinenceWithdrawnNCT00523068Phase 4
• Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.CompletedNCT00481728Phase 1
• ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)TerminatedNCT00439192Phase 2
• Effects Of Detrol LA On Memory And Cognition In Elderly PopulationCompletedNCT00411437Phase 4
• Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy SubjectsCompletedNCT00332137Phase 2
• Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment OutcomeStatus unknownNCT00313924Phase 4
• Detrol LA In Men With Overactive Bladder.CompletedNCT00282932Phase 4
• Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.CompletedNCT00230789Phase 4
• Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in WomenCompletedNCT00143481Phase 4
• Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release TabletCompletedNCT00139724Phase 3
• A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive BladderCompletedNCT00137397Phase 4

← Tolterodine overview